>Organic revenue and EBITDA growth beats forecasts in Q1 - Nexi has just published its Q1 2024 results. Results beat forecasts with organic revenue growth of +6.0% to € 782m (vs ODDO BHF / consensus = +4.5/+5.3% to € 775m/€ 776m - recap 2023 = +7.0%) and pro forma EBITDA growth of +8.6% to € 362m (vs ODDO BHF / consensus = +6.1/+6.5% to € 356m/€ 355m), i.e. a +112bp improvement in the EBITDA margin to 46.3% (vs ODDO BHF / consensus = 46.0/45.7%).All activities r...
>Q1 in line on sales, below on EBIT - Q1 sales grew by 83% y-o-y and 6% q-o-q to $ 398m (US $ 347m, Japan $ 18m and EMEA $ 31m), reflecting the strong medical need in myasthenia gravis, the quality of products (i.e. Vyvgart and Vyvgart Hytrulo), as well as the excellent execution of the commercial rollout. The product should remain on this growth trajectory to achieve peak sales estimated at $ 11bn (vs the consensus at $ 11bn) in 2035, driven by the recent launch of ...
>Q4 24 > forecasts, driven by royalties and licences also far > forecasts - Revenues for Q4 24 came to $ 928m i.e. +47% y-o-y, > the consensus of $ 881m and guidance of $ 900-850m, giving an average point of $ 875m. This performance can be explained notably by royalties of $ 514m at +37% y-o-y (after +11% in Q3), > the consensus of $ 505m, reflecting greater penetration for ARMv9 with notably brisk growth on the smartphone market as well as infrastructure. It is also ...
>Croissance organique du CA et de l’EBITDA au-dessus des attentes au T1 - Nexi vient de publier ses résultats au titre du T1 2024. Ils dépassent les attentes avec un CA en croissance organique de 6.0% à 782 M€ (vs ODDO BHF / consensus = +4.5/+5.3% à 775/776 M€ - rappel 2023 = +7.0%) et un EBITDA en progression proforma de 8.6% à 362 M€ (vs ODDO BHF / consensus = +6.1/+6.5% à 356/355 M€) soit une marge d’EBITDA en hausse comparable de 112 pb à 46.3% (vs ODDO BHF / con...
>T1 en ligne sur les ventes, en dessous sur l’EBIT - Les ventes T1 progressent de 83% y-o-y et de 6% q-o-q pour atteindre 398 M$ (US 347 M$, Japon 18 M$ et EMEA 31 M$), reflétant le fort besoin médical dans la Myasthénie Gravis, la qualité des produits (i.e. Vyvgart et Vyvgart Hytrulo), ainsi que l’excellente exécution du déploiement commercial. Le produit devrait rester sur cette trajectoire de croissance pour atteindre un peak sales estimé à 11 Md$ (vs css 11 Md$) ...
>Données de sécurité positives et une efficacité confirmée - Medincell et son partenaire Teva ont communiqué hier à la mi-journée une mise à jour de leur étude de phase 3 SOLARIS évaluant mdc-TJK (olanzapine) pour le traitement des épisodes psychotiques chez les patients souffrants de schizophrénie. Le profil de sécurité, point important de l’étude, ressort positif avec 0 cas de PDSS (Post-injection delirium/sedation syndrome) rapporté après le dosage de 80% des 3600 ...
>Résultats T4 24 > aux attentes, tirés par des royalties et des licences également nettement > aux attentes - Le CA du T4 24 ressort à 928 M$ soit +47% yoy, > au consensus de 881 M$ et une guidance de 850/900 M$ soit un point moyen de 875 M$. Cette performance s’explique notamment par des royalties de 514 M$ à +37% yoy (après +11% au T3), > au consensus de 505 M$, reflétant une pénétration accrue de ARMv9, avec notamment une forte croissance sur le marché des smartpho...
>Positive safety data and confirmed efficacy - At midday yesterday, Medincell and its partner Teva provided an update on their phase III SOLARIS study evaluating mdc-TJK (olanzapine) for the treatment of psychotic episodes in patients with schizophrenia. The safety profile, an important aspect of the study, was positive, with 0 cases of PDSS (post-injection delirium/sedation syndrome) reported after dosing 80% of the 3,600 injections required for the study. The effica...
>Contrasting performances in Q1 depending on the business - Rubis reported its Q1 2024 revenues yesterday evening. The group posted mixed performances:For Retail & Marketing (70% of EBITDA in 2023): Trends for volumes (+4%) and adjusted unit margins (-2%) were right in line with 2023. Europe and the Caribbean are in good shape, unlike Africa, hit by lacklustre economic trends in Kenya and headwinds in bitumen in Nigeria. Some currency losses are also expected in ...
>Key takeaways from the conference call - Following the publication of the Q1 2024 results yesterday morning, followed by the conference call with management, we would like to highlight the following points:The environment in terms of demand remained unchanged in Q1 2024, extending the trend seen in Q4 2023 with low volumes (0%). There are no clear signs of recovery, but there are some positive elements that need to be confirmed. Visibility is still too low to pe...
>Solid Q1 2024 results but order intake below expectation due to subdued demand in some markets - This morning, Jenoptik reported its Q1 2024 results above expectations. Revenues were € 256.1m above consensus at € 245.4m. EBITDA was € 44.5m, giving a margin of 17.4% above the consensus at € 40.6m and 16.5% driven by the improvement in earnings at non-photonic business and the good performance of ‘Advanced Photonic division’. EBIT came in at € 26m, i.e. a margin of 10....
>Solid Q1 2024 results but order intake below expectation due to subdued demand in some markets - This morning, Jenoptik reported its Q1 2024 results above expectations. Revenues were € 256.1m above consensus at € 245.4m. EBITDA was € 44.5m, giving a margin of 17.4% above the consensus at € 40.6m and 16.5% driven by the improvement in earnings at non-photonic business and the good performance of ‘Advanced Photonic division’. EBIT came in at € 26m, i.e. a margin of 10....
>Outperform reiterated, target price raised to € 45 vs € 40 despite the warning - Following the publication of Q2 2024 results that came in a shade above of expectations yesterday and despite the downward revision to the guidance for 2024 (the weakness of demand in automobile and the deepening of the correction in industry) the stock rebounded strongly (+13%). Despite this revision, the market above all retained that 1/ Infineon has indicated that it has de-risked its...
>The premium can be justified by short-term growth and a well-stocked pipeline - AZN certainly benefits from: i/ attractive short-term core EPS growth for 2023-2027, up 11.5% (+12.7% expected this year), and undoubtedly the most well-stocked pipeline in the industry. These elements partly justify the market premium for its 2025 P/E (+43% vs sector median), leading to a 2023-2027 PEG of 1.6x vs 1.3x for the sector. However, this growth should be more timorous in 2...
>Des performances disparates au T1 selon les activités - Rubis a publié hier soir son CA au titre du T1 2024. Nous retiendrons des performances mitigées :Pour Retail & Marketing (70% de l’EBITDA 2023) : Les tendances de volumes (+4%) et de marges unitaires ajustées (-2%) sont exactement en ligne avec 2023. L’Europe et les Caraïbes sont bien orientées contrairement à l’Afrique qui pâtit d’une économie sous pression au Kenya et de vents contraires dans le bitume au...
>Principaux points à retenir suite à la conférence téléphonique - Suite à la publication des résultats trimestriels hier matin suivie par la conférence téléphonique des dirigeants, nous retiendrons :L'environnement reste inchangé au T1 24 au niveau de la demande, dans la continuité du T4 2023 avec de faibles volumes (0%). Il n'y a pas de signe clair de reprise mais quelques éléments positifs qui doivent être confirmés. La visibilité est toujours présentée comme t...
>Une prime qui se justifie par une croissance CT et un pipeline exhaustif - AZN bénéficie sans nulle doute i/ d’une croissance CT attractive Core BPA 2023-2027 en hausse de 11.5% (+12.7% att cette année) et d’un pipeline certainement le plus exhaustif de l’industrie. Ces aspects justifient en partie la prime octroyée par le marché en termes de PE 25e (+43% vs médiane sectorielle) conduisant à un PEG 23/27e de 1.6x vs 1.3x pour le secteur. En revanche cette croiss...
>Opinion Surperformance réitérée, OC relevé à 45 € vs 40 € malgré le warning - Suite à la publication des résultats T2 24 légèrement supérieurs aux attentes hier et malgré la révision en baisse de la guidance 2024 (faiblesse de la demande dans l’automobile et approfondissement de la correction dans l’industrie), le titre a fortement rebondi (+13%). Malgré cette révision, le marché a en effet surtout retenu que 1/ IFX a indiqué avoir dérisqué sa guidance et qu’il s’agi...
>EBITDA down in Q1 but not by as much as expected - Arkema has just reported its Q1 2024 results. EBITDA was down 5% to € 350m, 3% above forecasts (ODDO BHF / consensus = € 340m/€ 341m) and 6% above the guidance (€ 331m corresponding to Q4 2023).The group continues to operate in a context of weak demand (volumes = 0%, of which +3% for speciality chemicals and -28% intermediates – as a reminder Q4 2023= +2%). By division, adhesives and advanced materials delivere...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.